OC 3 - OneChain Immunotherapeutics
Alternative Names: OC-3-OneChain ImmunotherapeuticsLatest Information Update: 08 Feb 2023
At a glance
- Originator OneChain Immunotherapeutics
- Class Antineoplastics; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; Intraepithelial lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Cancer
Most Recent Events
- 28 Dec 2022 Early research in Cancer in Spain (Parenteral) (OneChain Immunotherapeutics pipeline, December 2022)